I am off to the Australian National University this afternoon to meet Will Grant‘s Science and Public Policy Group.
The topic of our meeting will be performance enhancing drugs. It is a good time to be discussing these issues.
In London at the moment the aim has been to “carry out an unprecedented number of tests to ensure the health and rights of the athletes, and that the integrity of the Games is upheld” at the Harlow Anti-Doping Laboratory. The facility has been supplied by pharmaceutical company GlaxoSmithKline, a London 2012 partner. It is anticipated that 5,000 samples will be collected at the Olympic Games (an increase of over 10% from the Beijing 2008 Olympic Games). The London 2012 web site notes that “Over 1,000 London 2012 staff will work within the anti-doping process, with more than 150 scientists carrying out the testing.
Thus far three athletes have been charged with doping violations at the Games: Amine Laalou (Morocco); Ivan Tsikhan (Belarus); and Diego Palomeque (Colombia).
In addition to my post about the 2012 World Anti-Doping Agency’s Code, I thought I would alert Will’s group to:
I thought too that two recent Conversation posts might be of interest:
- Macdonald Christie’s discussion of human testing of illicit drugs (3 August)
- Monika Merkes‘ consideration of animal model tests for new drugs (6 Augiust)
I am hopeful that this will give us a great deal to talk about. Perhaps a good starting point will be the first week debate about Ye Shiwen’s swimming performances at the Games. Or perhaps methylhexaneamine.